AbCellera initiated with a Buy at JonesResearch

JonesResearch analyst Debanjana Chatterjee initiated coverage of AbCellera (ABCL) with a Buy rating and $11 price target AbCellera’s validated antibody discovery platform has advanced 19 molecules into the clinic across internal and partnered programs spanning multiple indications, notes the analyst, who says the company’s capabilities are “best illustrated” by its collaboration with Eli Lilly (LLY).